ArticleTherapeutic advances in gastroenterology2012
Prucalopride: safety, efficacy and potential applications.
Article in Therapeutic advances in gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Chronic constipation: A review of literature.Medicine · 2018Pooled it
- [Is the pharmacological treatment of constipation in palliative care evidence based? : a systematic literature review].Schmerz (Berlin, Germany) · 2012Pooled it
- Recent Developments in Oral Drug Delivery of Prokinetic Agents: Nanoparticles and Beyond.Current drug delivery · 2026Review
- The Association between Hormone Replacement Therapy and Gastroparesis in Post-Menopausal Women: A Worldwide Database Analysis.Journal of personalized medicine · 2024Article
- Creating a data dictionary for pediatric autonomic disorders.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2023Article
- Itopride increases the effectiveness of the management of opioid-induced constipation in palliative care patients: an observational non-interventional study.Archives of medical science : AMS · 2022Article
- Current Opinion on Prucalopride in Gastroparesis and Chronic Constipation Treatment: A Focus on Patient Selection and Safety.Therapeutics and clinical risk management · 2021Review
- Small intestinal bacterial overgrowth in systemic sclerosis.Journal of scleroderma and related disorders · 2020Review
- Appropriate Use of Laxatives in the Older Person.Drugs & aging · 2019Review
- Sacral nerve stimulation in slow-transit constipation: effectiveness at 5-year follow-up.International journal of colorectal disease · 2019Article
- Current and Emerging Therapeutic Options for Gastroparesis.Gastroenterology & hepatology · 2018Article
- Gut Movements: A Review of the Physiology of Gastrointestinal Transit.Digestive diseases and sciences · 2018Review
- Prucalopride inhibits the glioma cells proliferation and induces autophagy via AKT-mTOR pathway.BMC neurology · 2018Article
- Prokinetics in the Management of Functional Gastrointestinal Disorders.Current gastroenterology reports · 2017Review
- Diverticulosis today: unfashionable and still under-researched.Therapeutic advances in gastroenterology · 2016Review
- Review
- Current and Emerging Medical Therapies for Gastroparesis.Current treatment options in gastroenterology · 2015Article
- Pharmacoeconomic study of chronic constipation in a secondary care centre.Irish journal of medical science · 2015Article
- Chronic constipation in the elderly: a primer for the gastroenterologist.BMC gastroenterology · 2015Article
- Prokinetics in the Management of Functional Gastrointestinal Disorders.Journal of neurogastroenterology and motility · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic constipation is a very common functional gastrointestinal disorder which can be associated with significant impairments in quality of life for some people with the condition. Its management has, traditionally, been based on dietary and lifestyle changes and the use of a variety of laxative agents. The evidence base for the efficacy of the latter is, in many cases, slim. Not surprisingly, many patients remain dissatisfied with laxatives thus leading to the development of more pharmacological approaches. Among these approaches is the use of prokinetic agents; while prior molecules have been troubled by lack of selectivity and cardiac side effects, the new agent, prucalopride, appears to be highly selective for the serotonin 5-HT4 receptor and is, therefore, a potent stimulator of gut motility. In three large pivotal randomized controlled trials, prucalopride has been effective in relieving the cardinal symptoms of chronic constipation; these effects have been sustained in open-label follow up for as long as 18 months. The safety profile has been encouraging and, especially so, the absence of arrhythmogenic potential. Studies in men, in constipation-predominant irritable bowel syndrome and in other motor disorders are eagerly awaited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.